The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Open accessAbstract
Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance, and IDO1 inhibition is an active area of drug development. Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway. Here, we show that enzymatically active TDO is expressed in a significant proportion of human tumors. In a preclinical model, TDO expression by tumors prevented their rejection by immunized mice. We developed a TDO inhibitor, which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors. Our results describe a mechanism of tumoral immune resistance based on TDO expression and establish proof-of-concept for the use of TDO inhibitors in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 5×
“We previously observed in a preclinical model that rejection of IDO1-expressing tumors was promoted by systemic treatment with an IDO1 inhibitor (4).”
BackgroundMethodInfluentialSelf-citationAn endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Terness, P., Bauer, T. M., Röse, L., Dufter, C., Watzlik, A., Simon, H., & Opelz, G. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020052 · Cited by 937
HUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2639 · Cited by 421
Simultaneous Measurement of Serum Tryptophan and Kynurenine by HPLC,
Widner, B., Werner, E. R., Schennach, H., Wachter, H., & Fuchs, D. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.12.2424 · Cited by 411
Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 398
Control of immune response by amino acid metabolism
Grohmann, U., & Bronte, V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00915.x · Cited by 308
Van den Eynde, B., Lethé, B., Van Pel, A., De Plaen, E., & Boon, T. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.6.1373 · Cited by 298
Self-citationKanai, M., Funakoshi, H., Takahashi, H., Hayakawa, T., Mizuno, S., Matsumoto, K., & Nakamura, T. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-8 · Cited by 273
Miller, C. L., Llenos, I. C., Dulay, J. R., Barillo, M. M., Yolken, R. H., & Weis, S. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.015 · Cited by 233
Yue, E. W., Douty, B., Wayland, B., Bower, M., Liu, X., Leffet, L., Wang, Q., Bowman, K. J., Hansbury, M. J., Liu, C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900518f · Cited by 219
Kohro, T., Tanaka, T., Murakami, T., Wada, Y., Aburatani, H., Hamakubo, T., & Kodama, T. (2004) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11.88 · Cited by 182
Dolušić, E., Larrieu, P., Moineaux, L., Stroobant, V., Pilotte, L., Colau, D., Pochet, L., Van den Eynde, B., Masereel, B., Wouters, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006782 · Cited by 181
Self-citationMelanoma drug wins US approval
Ledford, H. (2011) · Nature · doi:10.1038/471561a · Cited by 163
Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors
Röhrig, U. F., Awad, L., Grosdidier, A., Larrieu, P., Stroobant, V., Colau, D., Cerundolo, V., Simpson, A. J. G., Vogel, P., Van den Eynde, B. J., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9014718 · Cited by 163
Self-citationHigano, C. S., Small, E. J., Schellhammer, P. F., Yasothan, U., Gubernick, S. I., Kirkpatrick, P. N., & Kantoff, P. W. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3220 · Cited by 147
Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti
Suzuki, S., Toné, S., Takikawa, O., 俊一, 久., Kohno, I., & Minatogawa, Y. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3550425 · Cited by 135
New Therapies for Castration-Resistant Prostate Cancer
Longo, D. L. (2010) · New England Journal of Medicine · doi:10.1056/nejme1006300 · Cited by 128
Salter, M., Hazelwood, R., Pogson, C. I., Iyer, R., & Madge, D. J. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00006-l · Cited by 119
Antimicrobial and immunoregulatory properties of human tryptophan 2,3‐dioxygenase
Schmidt, S. K., Müller, A., Heseler, K., Woite, C., Spekker, K., MacKenzie, C. R., & Däubener, W. (2009) · European Journal of Immunology · doi:10.1002/eji.200939535 · Cited by 99
Eguchi, N., Watanabe, Y., Kawanishi, K., Hashimoto, Y., & Hayaishi, O. (1984) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(84)90579-4 · Cited by 73
Brändle, D., Bilsborough, J., Rülicke, T., Uyttenhove, C., Boon, T., & den Eynde, B. J. V. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199812)28:12<4010::aid-immu4010>3.0.co;2-5 · Cited by 64
Self-citationREN, Q., Robertson, S. J., Howe, D., Barrows, L. F., & Heinzen, R. A. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07447.x · Cited by 56
Induction of Tryptophan 2,3-Dioxygenase in the Mouse Endometrium during Implantation
Tatsumi, K., Higuchi, T., Fujiwara, H., Nakayama, T., Egawa, H., Itoh, K., Fujii, S., & Fujita, J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3115 · Cited by 55
Treating Cancer by Targeting the Immune System
Hwu, P. (2010) · New England Journal of Medicine · doi:10.1056/nejme1006416 · Cited by 49
Tryptophan Pyrrole Ring Cleavage Enzymes in Placenta
Minatogawa, Y., Suzuki, S., Ando, Y., Toné, S., & Takikawa, O. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0135-0_50 · Cited by 27
Cited by
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects
Badawy, A. A.-B. (2017) · International Journal of Tryptophan Research · doi:10.1177/1178646917691938 · Cited by 1,158
Immunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
“Nature 478, 197–203 7 Pilotte, L. et al. (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.”
BackgroundInfluential
Metadata
- Authors
- Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., & Van den Eynde, B. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2012-01-30
- Volume
- 109
- Issue
- 7
- Pages
- 2497-2502
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2087801719
- Cited by
- 572
- References
- 34
- FWCI
- 17.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.